newsfilter
← Latest News
Business Wire·

Travere Therapeutics Provides Corporate Update and 2026 Outlook

U.S. FILSPARI reaches all-time highs of 908 new PSFs and net product sales of approximately $103 million in 4Q 2025 Company positioned for successful commercial launch of FILSPARI in FSGS, if approved Pivotal Phase